{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T09:24:59Z","timestamp":1768728299200,"version":"3.49.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,4,21]],"date-time":"2013-04-21T00:00:00Z","timestamp":1366502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s40272-013-0023-7","type":"journal-article","created":{"date-parts":[[2013,4,20]],"date-time":"2013-04-20T14:55:00Z","timestamp":1366469700000},"page":"271-280","source":"Crossref","is-referenced-by-count":10,"title":["Cost of Biologics in the Treatment of Juvenile Idiopathic Arthritis: A Factor not to be Overlooked"],"prefix":"10.1007","volume":"15","author":[{"given":"Femke H. M.","family":"Prince","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisette W. A.","family":"van Suijlekom-Smit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,21]]},"reference":[{"key":"23_CR1","doi-asserted-by":"crossref","first-page":"c6434","DOI":"10.1136\/bmj.c6434","volume":"341","author":"FH Prince","year":"2010","unstructured":"Prince FH, Otten MH, van Suijlekom-Smit LW. Diagnosis and management of juvenile idiopathic arthritis. BMJ. 2010;341:c6434.","journal-title":"BMJ"},{"issue":"7","key":"23_CR2","first-page":"1520","volume":"29","author":"PJ Manners","year":"2002","unstructured":"Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol. 2002;29(7):1520\u201330.","journal-title":"J Rheumatol"},{"key":"23_CR3","doi-asserted-by":"crossref","unstructured":"Tupper SM, Rosenberg AM, Pahwa P, Stinson JN. Pain intensity variability and relationship with quality of life in youth with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2013;95(4):563\u2013570.","DOI":"10.1002\/acr.21850"},{"issue":"1","key":"23_CR4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1546-0096-10-33","volume":"10","author":"V Lundberg","year":"2012","unstructured":"Lundberg V, Lindh V, Eriksson C, Petersen S, Eurenius E. Health-related quality of life in girls and boys with juvenile idiopathic arthritis: self- and parental reports in a cross-sectional study. Pediatr Rheumatol Online J. 2012;10(1):33.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"23_CR5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.berh.2009.07.003","volume":"23","author":"BJ Prakken","year":"2009","unstructured":"Prakken BJ, Albani S. Using biology of disease to understand and guide therapy of JIA. Best Pract Res Clin Rheumatol. 2009;23(5):599\u2013608.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"23_CR6","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"3","key":"23_CR7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/11588140-000000000-00000","volume":"13","author":"MW Beresford","year":"2011","unstructured":"Beresford MW. Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy. Paediatr Drugs. 2011;13(3):161\u201373.","journal-title":"Paediatr Drugs"},{"issue":"4","key":"23_CR8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465\u201382.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"23_CR9","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clim.2011.10.003","volume":"142","author":"G Dueckers","year":"2012","unstructured":"Dueckers G, Guellac N, Arbogast M, Dannecker G, Foeldvari I, Frosch M, et al. Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol. 2012;142(2):176\u201393.","journal-title":"Clin Immunol"},{"issue":"4 Suppl 73","key":"23_CR10","first-page":"S157","volume":"30","author":"A Consolaro","year":"2012","unstructured":"Consolaro A, Negro G, Lanni S, Solari N, Martini A, Ravelli A. Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S157\u201362.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"23_CR11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/acr.20337","volume":"63","author":"WJ Ungar","year":"2011","unstructured":"Ungar WJ, Costa V, Hancock-Howard R, Feldman BM, Laxer RM. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken). 2011;63(1):111\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"Suppl 1","key":"23_CR12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000229759","volume":"72","author":"K Minden","year":"2009","unstructured":"Minden K. Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res. 2009;72(Suppl 1):20\u20135.","journal-title":"Horm Res"},{"issue":"2","key":"23_CR13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.pcl.2012.03.014","volume":"59","author":"PJ Gowdie","year":"2012","unstructured":"Gowdie PJ, Tse SM. Juvenile idiopathic arthritis. Pediatr Clin North Am. 2012;59(2):301\u201327.","journal-title":"Pediatr Clin North Am"},{"issue":"6","key":"23_CR14","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/art.34343","volume":"64","author":"CA Wallace","year":"2012","unstructured":"Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O\u2019Neil KM, Zeft AS, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64(6):2012\u201321.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"23_CR15","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","volume":"70","author":"P Tynjala","year":"2011","unstructured":"Tynjala P, Vahasalo P, Tarkiainen M, Kroger L, Aalto K, Malin M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011;70(9):1605\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"23_CR16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545\u201355.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"23_CR17","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","volume":"64","author":"EM DeWitt","year":"2012","unstructured":"DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2012;64(7):1001\u201310.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"23_CR18","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1002\/art.11439","volume":"48","author":"K Michaud","year":"2003","unstructured":"Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum. 2003;48(10):2750\u201362.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"23_CR19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/art.1780380209","volume":"38","author":"H Mangge","year":"1995","unstructured":"Mangge H, Kenzian H, Gallistl S, Neuwirth G, Liebmann P, Kaulfersch W, et al. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum. 1995;38(2):211\u201320.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"23_CR20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/rheumatology\/kem271","volume":"47","author":"M Frosch","year":"2008","unstructured":"Frosch M, Roth J. New insights in systemic juvenile idiopathic arthritis\u2013from pathophysiology to treatment. Rheumatology (Oxford). 2008;47(2):121\u20135.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"23_CR21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342(11):763\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"23_CR22","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.34348","volume":"64","author":"T Beukelman","year":"2012","unstructured":"Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64(4):1263\u201371.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"23_CR23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrrheum.2010.142","volume":"6","author":"PJ Hashkes","year":"2010","unstructured":"Hashkes PJ, Uziel Y, Laxer RM. The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol. 2010;6(10):561\u201371.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"23_CR24","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202\u20139.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"23_CR25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/BOR.0b013e32825a6a68","volume":"19","author":"S Ringold","year":"2007","unstructured":"Ringold S, Wallace CA. Measuring clinical response and remission in juvenile idiopathic arthritis. Curr Opin Rheumatol. 2007;19(5):471\u20136.","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"23_CR26","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/rheumatology\/keq432","volume":"50","author":"FH Prince","year":"2011","unstructured":"Prince FH, de Bekker-Grob EW, Twilt M, van Rossum MA, Hoppenreijs EP, ten Cate R, et al. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register. Rheumatology (Oxford). 2011;50(6):1131\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"23_CR27","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/ard.2003.008516","volume":"63","author":"K Minden","year":"2004","unstructured":"Minden K, Niewerth M, Listing J, Biedermann T, Schontube M, Zink A. Burden and cost of illness in patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(7):836\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"23_CR28","first-page":"863","volume":"27","author":"K Minden","year":"2009","unstructured":"Minden K, Niewerth M, Listing J, Mobius D, Thon A, Ganser G, et al. The economic burden of juvenile idiopathic arthritis-results from the German paediatric rheumatologic database. Clin Exp Rheumatol. 2009;27(5):863\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"23_CR29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.22463","volume":"57","author":"S Bernatsky","year":"2007","unstructured":"Bernatsky S, Duffy C, Malleson P, Feldman DE, St Pierre Y, Clarke AE. Economic impact of juvenile idiopathic arthritis. Arthritis Rheum. 2007;57(1):44\u20138.","journal-title":"Arthritis Rheum"},{"key":"23_CR30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1546-0096-8-20","volume":"8","author":"LN Moorthy","year":"2010","unstructured":"Moorthy LN, Peterson MG, Hassett AL, Lehman TJ. Burden of childhood-onset arthritis. Pediatr Rheumatol Online J. 2010;8:20.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"7","key":"23_CR31","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s00296-011-1894-y","volume":"32","author":"IK Yucel","year":"2012","unstructured":"Yucel IK, Seyahi E, Kasapcopur O, Arisoy N. Economic impact of juvenile idiopathic arthritis and familial Mediterranean fever. Rheumatol Int. 2012;32(7):1955\u201362.","journal-title":"Rheumatol Int"},{"issue":"11","key":"23_CR32","first-page":"2286","volume":"31","author":"J Haapasaari","year":"2004","unstructured":"Haapasaari J, Kautiainen HJ, Isomaki HA, Hakala M. Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2286\u20139.","journal-title":"J Rheumatol"},{"issue":"7","key":"23_CR33","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/rheumatology\/ken039","volume":"47","author":"J Thornton","year":"2008","unstructured":"Thornton J, Lunt M, Ashcroft DM, Baildam E, Foster H, Davidson J, et al. Costing juvenile idiopathic arthritis: examining patient-based costs during the first year after diagnosis. Rheumatology (Oxford). 2008;47(7):985\u201390.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"23_CR34","first-page":"952","volume":"19","author":"SH Allaire","year":"1992","unstructured":"Allaire SH, DeNardo BS, Szer IS, Meenan RF, Schaller JG. The economic impacts of juvenile rheumatoid arthritis. J Rheumatol. 1992;19(6):952\u20135.","journal-title":"J Rheumatol"},{"issue":"12","key":"23_CR35","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1517\/14712598.2010.532785","volume":"10","author":"JF Swart","year":"2010","unstructured":"Swart JF, Barug D, Mohlmann M, Wulffraat NM. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Expert Opin Biol Ther. 2010;10(12):1743\u201352.","journal-title":"Expert Opin Biol Ther"},{"issue":"17","key":"23_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta6170","volume":"6","author":"C Cummins","year":"2002","unstructured":"Cummins C, Connock M, Fry-Smith A, Burls A. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept. Health Technol Assess. 2002;6(17):1\u201343.","journal-title":"Health Technol Assess"},{"key":"23_CR37","doi-asserted-by":"crossref","unstructured":"Barnabe C, Thanh NX, Ohinmaa A, Homik J, Barr SG, Martin L, et al. Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission. Ann Rheum Dis. 2012. doi: 10.1136\/annrheumdis-2012-201918 .","DOI":"10.1136\/annrheumdis-2012-201918"},{"key":"23_CR38","first-page":"S72","volume":"30","author":"G Furneri","year":"2012","unstructured":"Furneri G, Mantovani LG, Belisari A, Mosca M, Cristiani M, Bellelli S, et al. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol. 2012;30:S72\u201384.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"23_CR39","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1136\/ard.2008.101030","volume":"68","author":"FH Prince","year":"2009","unstructured":"Prince FH, Twilt M, Simon SC, van Rossum MA, Armbrust W, Hoppenreijs EP, et al. When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68(7):1228\u20139.","journal-title":"Ann Rheum Dis"},{"key":"23_CR40","unstructured":"Withdrawal of etanercept after successful treatment of juvenile idiopathic arthritis (ABC-STOP). Netherlands Trial Register Number: NCT01287715."},{"key":"23_CR41","unstructured":"BeSt for kids: comparing treatment strategies in juvenile idiopathic arthritis. Netherlands Trial Register Number: NTR1574."},{"issue":"9","key":"23_CR42","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1136\/annrheumdis-2011-200942","volume":"71","author":"M Bulatovic","year":"2012","unstructured":"Bulatovic M, Heijstek MW, Van Dijkhuizen EH, Wulffraat NM, Pluijm SM, de Jonge R. Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71(9):1484\u20139.","journal-title":"Ann Rheum Dis"},{"key":"23_CR43","doi-asserted-by":"crossref","unstructured":"Postepski J, Kobusinska K, Olesinska E, Osinska V, Opoka-Winiarska V. Clinical remission in juvenile idiopathic arthritis after termination of etanercept. Rheumatol Int. 2012. doi: 10.1007\/s00296-012-2468-3 .","DOI":"10.1007\/s00296-012-2468-3"},{"issue":"6","key":"23_CR44","first-page":"919","volume":"28","author":"P Pratsidou-Gertsi","year":"2010","unstructured":"Pratsidou-Gertsi P, Trachana M, Pardalos G, Kanakoudi-Tsakalidou F. A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission. Clin Exp Rheumatol. 2010;28(6):919\u201322.","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"23_CR45","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3899\/jrheum.100219","volume":"37","author":"A Remesal","year":"2010","unstructured":"Remesal A, Inocencio DE, Merino R, Garcia-Consuegra J. Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis. J Rheumatol. 2010;37(9):1970\u20131.","journal-title":"J Rheumatol"},{"issue":"9","key":"23_CR46","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096\u2013106.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"23_CR47","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747\u201354.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"23_CR48","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/art.33342","volume":"64","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64(2):557\u201367.","journal-title":"Arthritis Rheum"},{"issue":"9617","key":"23_CR49","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998\u20131006.","journal-title":"Lancet"},{"issue":"25","key":"23_CR50","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F Benedetti De","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385\u201395.","journal-title":"N Engl J Med"},{"issue":"7","key":"23_CR51","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/RHU.0b013e3181ba3c6f","volume":"15","author":"JG Feito","year":"2009","unstructured":"Feito JG, Pereda CA. Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists. J Clin Rheumatol. 2009;15(7):363\u20135.","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"23_CR52","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1136\/ard.2008.092106","volume":"68","author":"J Narvaez","year":"2009","unstructured":"Narvaez J, Diaz-Torne C, Juanola X, Geli C, Llobet JM, Nolla JM, et al. Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68(4):607\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"23_CR53","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10067-011-1720-7","volume":"30","author":"EI Alexeeva","year":"2011","unstructured":"Alexeeva EI, Valieva SI, Bzarova TM, Semikina EL, Isaeva KB, Lisitsyn AO, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011;30(9):1163\u201372.","journal-title":"Clin Rheumatol"},{"key":"23_CR54","unstructured":"Lovell DJ GE, Kimura Y, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (SJIA). Arthritis Rheum. 2009;60(Suppl 10):2053."},{"issue":"9636","key":"23_CR55","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383\u201391.","journal-title":"Lancet"},{"issue":"8","key":"23_CR56","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810\u201320.","journal-title":"N Engl J Med"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-013-0023-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-013-0023-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-013-0023-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T09:29:46Z","timestamp":1715246986000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-013-0023-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,21]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["23"],"URL":"https:\/\/doi.org\/10.1007\/s40272-013-0023-7","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,21]]}}}